UCB Commences Phase 3 Lacosamide Study In Asia As Adjunctive Therapy In Adults With Partial-Onset Seizures

UCB announces the start of a new phase 3 clinical trial of lacosamide in Japan and China which is designed to investigate the efficacy and safety of lacosamide as adjunctive therapy in adult patients with partial-onset seizures. UCB obtained Japanese rights to lacosamide at the end of 2010 and since then holds the world-wide rights to development and marketing. Initial results from this phase 3 study are expected in the first half of 2015. "At UCB, we are committed to improving the lives of people living with epilepsy...

Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/c28j2ryoT5w/253040.php

sport news news auto sport